阿帕替尼联合放化疗治疗晚期结直肠癌2例并文献复习

›› 2019, Vol. 4 ›› Issue (8): 39-42.

阿帕替尼联合放化疗治疗晚期结直肠癌2例并文献复习

张建依1，张静2，王剑华2，段赛竹2，张荣生2*

（1.大理大学临床医学院，云南大理671000；2.大理大学第一附属医院，云南大理671000）

收稿日期:2018-09-28 修回日期:2019-04-10 出版日期:2019-08-15 发布日期:2019-08-15
通讯作者: 张荣生，主任医师，E-mail：zhangrs0678@qq.com.
作者简介:张建依，硕士研究生，主要从事肿瘤内科学研究.

Apatinib Combined with Radiochemotherapy for Advanced Colorectal Cancer in 2 Cases and
Literature Review

Zhang Jianyi1, Zhang Jing2, Wang Jianhua2, Duan Saizhu2, Zhang Rongsheng2*

（1. Clinical College, Dali University, Dali, Yunnan 671000, China; 2. The First Affiliated Hospital of Dali University,
Dali, Yunnan 671000, China）

Received:2018-09-28 Revised:2019-04-10 Online:2019-08-15 Published:2019-08-15

摘要/Abstract

摘要：

目的：回顾分析阿帕替尼联合放化疗治疗晚期结直肠癌的疗效及安全性。方法：对2例晚期结直肠癌患者阿帕替尼联合
放化疗治疗的疗效及安全性进行分析及文献复习。结果：2例患者随访12个月，均达到疾病稳定，总生存期获益。主要不良反应
为乏力、口腔疼痛，经处理或调整剂量后均能耐受。结论：阿帕替尼联合放化疗治疗晚期结直肠癌的疗效肯定，不良反应可耐受。

关键词: 晚期结直肠癌, 阿帕替尼, 联合治疗, 疗效分析

Abstract:

Objective: To retrospectively analyze the efficacy and safety of apatinib combined with radiochemotherapy in the
treatment of advanced colorectal cancer. Methods: The efficacy and safety of two patients with advanced colorectal cancer treated with
apatinib combined with radiochemotherapy were analyzed and related literatures were reviewed. Results: Two patients were followed
up for 12 months, all of whom had achieved stable disease and benefited from overall survival. The main adverse reactions were fatigue,
oral pain, and were tolerable after treatment or dose adjustment. Conclusion: The efficacy of apatinib combined with radiochemotherapy
in the treatment of advanced colorectal cancer is positive, and adverse reactions can be tolerated.

Key words: advanced colorectal cancer, apatinib, combination therapy, curative effect analysis

中图分类号:

R735.3

张建依, 张静, 王剑华, 段赛竹, 张荣生. 阿帕替尼联合放化疗治疗晚期结直肠癌2例并文献复习[J]. , 2019, 4(8): 39-42.

ZHANG Jian-Yi, ZHANG Jing, WANG Jian-Hua, DUAN Sai-Zhu, ZHANG Rong-Sheng. Apatinib Combined with Radiochemotherapy for Advanced Colorectal Cancer in 2 Cases and
Literature Review[J]. , 2019, 4(8): 39-42.

参考文献

〔1〕CHEN W，SUN K，ZHENG R，et al. Cancer incidence and
mortality in China，2014〔J〕. Chin J Cancer Res，2018，30
（1）：1-12.
〔2〕秦叔逵，李进. 阿帕替尼治疗胃癌的临床应用专家共
识〔J〕. 临床肿瘤学杂志，2015，20（9）：841-847.
〔3〕LI J，ZHAO X，CHEN L，et al. Safety and pharmacokinetics
of novel selective vascular endothelial growth factor recep?
tor-2 inhibitor YN968D1 in patients with advanced malig?
nancies〔J〕. BMC Cancer，2010，10：529.
〔4〕LI J，QIN S，XU J，et al. Apatinib for Chemotherapy-Refrac?
tory Advanced Metastatic Gastric Cancer：Results From a
Randomized，Placebo-Controlled，Parallel-Arm，Phase Ⅱ
Trial〔J〕. J Clin Oncol，2013，31（26）：3219-3225.

〔5〕LI J，QIN S，XU J，et al. Randomized，Double-Blind，Placebo-
Controlled Phase Ⅲ Trial of Apatinib in Patients With
Chemotherapy-Refractory Advanced or Metastatic Adeno?
carcinoma of the Stomach or Gastroesophageal Junction〔J〕.
J Clin Oncol，2016，34（13）：1448-1454.
〔6〕HU X，CAO J，HU W，et al. Multicenter phase Ⅱ study of
Apatinib in non- triple- negative metastatic breast can?
cer〔J〕. BMC Cancer，2014，14：820.
〔7〕HU X，ZHANG J，XU B ，et al. Multicenter phase Ⅱ study
of apatinib，a novel VEGFR inhibitor in heavily pretreated
patients with metastatic triple-negative breast cancer〔J〕.
Int J Cancer，2014，135（8）：1961-1969.
〔8〕涂艳，彭枫. 阿帕替尼治疗恶性肿瘤的临床研究进展〔J〕.
中国肿瘤临床，2016，43（12）：545-548.
〔9〕孙培培，张龙，张泰，等. 单药阿帕替尼治疗二线及二线
以上化疗失败的晚期大肠癌患者疗效分析〔J〕. 临床肿
瘤学杂志，2017，22（7）：646-649.
〔10〕麻国新，甄书漫. 阿帕替尼治疗直肠癌术后放化疗后肺
转移1例〔J〕. 中国肿瘤临床，2016，43（23）：1068.
〔11〕彭雨，李海涛，杨文丽，等. 阿帕替尼在既往二线及二线以
上治疗失败后的晚期肝细胞癌中的临床疗效分析〔J〕.
徐州医学院学报，2017，37（3）：178-181.

[1]	陈宇，文兴扬，石艳葵，宋福钢，杨光成，张雪辉. 围生期心肌病合并心力衰竭32例疗效分析[J]. J4, 2015, 14(10): 20-22.
[2]	李秀珠, 刘昆娥. 利多卡因和碘甘油治疗RAU的临床疗效观察[J]. J4, 2011, 10(2): 56-57.